$LLY

Yuffa Ilya sold $2.9M of LLY

Yuffa Ilya (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares of ELI LILLY & Co (LLY) at $1150.77 ($2.88M total) on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yuffa Ilya
Published Jun 11, 2026, 8:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LLY
Neutral
high confidence
Mentioned
$LLY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LLYNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but 10b5-1 plans generally reduce the informational content versus discretionary sales.

02

Market read

A $2.88M LLY insider sale was disclosed, but it is pre-arranged under 10b5-1, limiting actionable fundamental implications.

03

What to watch

The article provides only the sale details; it does not state whether other insiders or large holders changed positions around the same time.

Relevance 5/10Novelty 6/10Timing: Filed June 11; sale executed June 10

Background

The article is a primary-source SEC Form 4 insider transaction disclosure (open-market sale) for LLY.

Company-level read

Ticker impact

$LLYNeutralHigh confidence
Context

SEC Form 4 shows EVP Yuffa Ilya sold 2,500 shares of LLY for about $2.88M on a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an open-market sale under a pre-arranged 10b5-1 plan, with no accompanying fundamental or regulatory catalyst disclosed.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal risk management or diversification, which some traders may still fade.

Key entities

  • ELI LILLY & Co

    Company whose shares were sold by an executive under a 10b5-1 plan.

  • Yuffa Ilya

    EVP & President, LLY USA & Global Capabilities; sold 2,500 shares.

Related articles

$LLYHighAI 9/10

Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook

Eli Lilly reported Q2 revenue of $23.0B, up 48% year over year, and raised full-year revenue guidance to $85B-$87B from $82B-$85B. Mounjaro revenue rose 91% to $9.9B and Zepbound 46% to $4.9B. The company also increased R&D and marketing costs and noted lower realized prices and higher acquisition-related charges.

$LLYMedAI 8/10

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly (LLY) reported Q2 U.S. revenue up 33% led by ZEPBOUND and MOUNJARO volume, while U.S. price fell 3% (9% excluding rebate and discount estimate changes). International revenue rose in constant currency, with MOUNJARO a key driver. Lilly raised its 2026 revenue outlook to $85B-$87B and guided non-GAAP EPS $35.50-$36.50. It also discussed Medicare GLP-1 coverage expansion and retatrutide Phase III results.

$LLYMedAI 8/10

📊 PRO: This Week in Visuals

The article is a PRO weekly roundup of business and earnings visuals, highlighting multiple public companies. It includes a detailed Eli Lilly section: Q2 revenue rose 48% Y/Y to $23.0B, adjusted EPS was $8.38, and GLP-1 sales grew with Mounjaro and Zepbound. Lilly raised FY26 revenue guidance to $85–$87B.

$LLYMedAI 8/10

Eli Lilly and Company Q2 2026 Earnings Call Summary

Eli Lilly reported Q2 2026 drivers including 48% revenue growth, with Zepbound and Mounjaro adding $6.3B incremental growth versus prior year, and gross margin rising to 86.3%. Full-year revenue guidance was raised to $85B–$87B. Management discussed Foundayo U.S. scaling, Medicare GLP-1 Bridge access for 20M Americans, and planned retatrutide registrations in Q1 2027.

$LLYHighAI 9/10

Eli Lilly stock jumps as GLP-1 sales widen Novo lead

Eli Lilly shares rose up to 7% after Q2 revenue jumped 48% to $22.97B, beating Wall Street by over $2B. Mounjaro and Zepbound totaled $14.87B, about 65% of revenue. Lilly lifted its 2026 outlook to $85B-$87B. Novo Nordisk also raised guidance, but U.S.-listed shares fell after Wegovy pill sales missed expectations.